Actelion, Merck Enter Oral Renin Inhibitor Pact Worth Up To $272M
Swiss biopharmaceutical firm Actelion Ltd. added $10 million to its cash pile, on the strength of an exclusive alliance with Merck & Co. Inc. in the area of oral renin inhibitors. (BioWorld International)
